Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery

This is a Phase 3 trial to compare SRG-514 (active pharmaceutical ingredient \[API\]: ketorolac) administered intraoperatively to the tumor resection cavity with standard-of-care (SOC) versus SOC alone in participants with clinical stage II-III triple negative breast cancer (TNBC) undergoing breast-conserving surgery (BCS) who are neoadjuvant therapy naïve.

NCT Number	NCT07723469
Lead Sponsor	SURGE Therapeutics
Conditions	TNBC - Triple-Negative Breast Cancer
Enrollment	400 participants
Start Date	2026-10
Primary Completion	2034-10 (estimated)
Study Completion	2034-10 (estimated)
Updated on ClinicalTrials.gov	2026-07-23